Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Squamous NSCLC
Activation of T-cell function has become a main focus of immunotherapeutic approaches aimed at enhancing an anticancer immune response and suppressing mechanisms used by tumor cells for immune evasion.
Lung cancer is the leading cause of cancer-related mortality worldwide, with approximately 1.6 million deaths annually.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
